3,5‐Dibenzoyl‐4‐(3‐phenoxyphenyl)‐1,4‐dihydro‐2,6‐dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility
- 1 February 2004
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 141 (3) , 415-422
Abstract
The aim of this study was to investigate the effects of 3,5‐diacetyl‐ (DP1–DP5) and 3,5‐dibenzoyl‐1,4‐dihydropyridines (DP6–DP11) on vascular functionsin vitro, by comparing their mechanical and electrophysiological actions in rat aorta rings and single rat tail artery myocytes, respectively, and to quantify their multidrug resistance (MDR)‐reversing activity in L5178 Y mouse T‐lymphoma cells transfected with MDR1 gene. In rat aorta, the 11 compounds tested, but 3,5‐dibenzoyl‐4‐(3‐phenoxyphenyl)‐1,4‐dihydro‐2,6‐dimethylpyridine (DP7), 3,5‐dibenzoyl‐4‐(3‐chlorophenyl)‐1,4‐dihydro‐2,6‐dimethylpyridine (DP9), 3,5‐dibenzoyl‐4‐(4‐chlorophenyl)‐1,4‐dihydro‐2,6‐dimethylpyridine (DP10) and 3,5‐dibenzoyl‐4‐phenyl‐1,4‐dihydro‐2,6‐dimethylpyridine (DP11), antagonized 60 mMK+(K60)‐induced contraction in a concentration‐dependent manner, with IC50(M) values ranging between 5.65 × 10−7and 2.23 × 10−5. The 11 dihydropyridines tested, but DP7, inhibited L‐type Ca2+current recorded in artery myocytes in a concentration‐dependent manner, with IC50(M) values ranging between 1.12 × 10−6and 6.90 × 10−5. The K+‐channel opener cromakalim inhibited the Ca2+‐induced contraction in K30 but not that evoked in K60. On the contrary, DP7 was ineffective in both experimental conditions. When the rings were preincubated with 1 mMNi2+plus 1μMnifedipine, the response to phenylephrine was significantly reduced by 2,5‐di‐t‐butyl‐1,4‐benzohydroquinone (BHQ), a well‐known endoplasmic reticulum Ca2+‐ATPase inhibitor. DP7 had no effects on this model system. In L5178 MDR cell line, the 11 dihydropyridines tested, but 3,5‐diacetyl‐4‐(2‐nitrophenyl)‐1,4‐dihydro‐2,6‐dimethylpyridine (DP1), 3,5‐diacetyl‐4‐(3‐phenoxyphenyl)‐1,4‐dihydro‐2,6‐dimethylpyridine (DP2) and 3,5‐diacetyl‐4‐(3‐chlorophenyl)‐1,4‐dihydro‐2,6‐dimethylpyridine (DP4), exhibited an MDR‐reversing activity, with IC50values ranging between 3.02 × 10−7and 4.27 × 10−5, DP7 being the most potent. In conclusion, DP7 may represent a lead compound for the development of potent dihydropyridine MDR chemosensitizers devoid of vascular effects. British Journal of Pharmacology(2004)141, 415–422. doi:10.1038/sj.bjp.0705635Keywords
This publication has 27 references indexed in Scilit:
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- 2,5‐Di‐t‐butyl‐1,4‐benzohydroquinone (BHQ) inhibits vascular L‐type Ca2+channelviasuperoxide anion generationBritish Journal of Pharmacology, 2001
- Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisersEuropean Journal of Cancer, 1996
- P-Glycoproteins and Multidrug ResistanceAnnual Review of Pharmacology and Toxicology, 1996
- Mechanisms of Drug-induced VasodilationJournal of Pharmacy and Pharmacology, 1994
- Comparative Effects of the Potassium Channel Openers Cromakalim and Pinacidil and the Cromakalim Analog U-89232 on Isolated Vascular and Cardiac TissuePharmacology, 1994
- The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi‐drug transporterInternational Journal of Cancer, 1993
- 2,5‐Di(tert‐butyl)‐1,4‐benzohydroquinone — a novel inhibitor of liver microsomal Ca2+ sequestrationFEBS Letters, 1987
- Use of tension measurements to delineate the mode of action of vasodilatorsJournal of Pharmacological Methods, 1987
- New developments in calcium ion channel antagonistsJournal of Medicinal Chemistry, 1983